














A dissertation submitted to Johns Hopkins University in conformity with the 









© 2016 Vesselin Ruslanov Penchev 




Cancer stem cells (CSCs) have been identified in a multitude of malignancies as 
an important regulator of tumor self-renewal and disease progression, and relapse.  Their 
functions indicate that targeting of CSCs will improve clinical outcomes.  Multiple 
phenotypic CSC populations have been isolated within the same disease, and their precise 
relationship is unclear.  Using pancreatic cancer as a model we demonstrate plasticity 
where non-overlapping CSC populations give rise to each other.  Surprisingly our results 
also indicate that non-CSCs could potentially give rise to CSCs.  Thus, mechanisms that 
are fundamental to the maintenance of CSCs need to be identified, since successful 
therapeutic strategies should target all sources of self-renewal within the tumor.  We 
identify modulation of actin filament dynamics as a novel mechanism for the regulation 
of CSC functions.  Pancreatic CSCs are characterized by a low polymerized to free actin 
ratio relative to the bulk of the tumor.  Inducing actin polymerization decreases CSC 
frequency and leads to the loss of self-renewal, and migratory capacity in vitro and a 
marked decrease of in vivo tumorigenicity.  Targeting actin dynamics decreases the 
frequency of three phenotypic CSC populations, suggesting that modulation of actin 
organization could be a fundamental mechanism for CSC regulation.  Modulators of actin 
dynamics specifically overexpressed in cancers can be utilized as therapeutic targets, and 
we used pharmacological inhibition of the cytoskeletal modulator Ezrin to decrease the 
tumorigenicity of human derived samples.  Our work demonstrates that investigating 
mechanisms of actin regulation in cancers could lead to the development of better 
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Identification of pancreatic 








Pancreatic ductal adenocarcinoma (PDAC) carries one of the worst prognoses of 
any malignancy and is the fourth leading cause of cancer related deaths in the United 
States (1). Despite advances in better understanding the basic biology of PDAC, survival 
rates have not significantly improved over the past 30 years, and less than five percent of 
patients remain alive 5-years after diagnosis.  Therefore, new treatments are needed for 
PDAC, and cancer stem cells (CSCs) have emerged as potential targets. 
CSCs represent phenotypically distinct cells that possess enhanced tumor-
initiating potential, self-renewal, and the ability to recapitulate the cellular heterogeneity 
of the original tumor (2).  Since these initial findings, additional features including their 
rarity, relative chemoresistance, and metastatic potential have been described, and these 
properties have allowed them to be referred to by more precise terms, such as tumor 
initiating cells. However, due to the heterogeneous properties exhibited by CSCs, it has 
been difficult to provide a label capable of encompassing all of these attributes.  
Therefore, we will refer to these specialized cell populations by the general term CSC 
throughout this review.  Although the identification of CSCs was limited to myeloid 
leukemias in the 1990s (3, 4), they have been described in an increasing number of solid 
tumors over the last decade, including multiple reports in PDAC (5-9).  Several aspects of 
the CSC hypothesis have been hotly debated (10-12), but most relevant is their clinical 
significance.  In PDAC, early data have suggested that the identification of CSCs in 
primary tumors is associated with shorter overall survival (6), and it is likely that 
additional functional properties including relative resistance to the standard cytotoxic 
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agent gemcitabine and enhanced metastatic potential are in part responsible for these 
findings (7, 13).  
 The identification and characterization of CSCs has generated novel hypotheses 
regarding the mechanisms involved in PDAC growth and dissemination, but several 
critical questions remain.  We will initially review studies identifying pancreatic CSCs 
and speculate how these distinct cell populations may be related to one another.  We will 
then discuss potential strategies to target pancreatic CSCs (14). 
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Identification of Pancreatic CSCs 
At the most basic level, the CSC hypothesis links phenotypically defined tumor 
cells with specific functional properties, and CSCs have been stringently defined by their 
ability to differentiate and self-renew (15).  The differentiation of CSCs gives rise to the 
full range of malignant cell types and histological recapitulation of the original tumor 
whereas self-renewal is responsible for maintaining long-term growth potential.  In most 
diseases, the ability of putative CSCs to form tumors has been evaluated using 
immunodeficient mice (e.g., NOD/Scid and NSG) followed by histological examination 
and serial transplantation to demonstrate self-renewal (16).  Although these mouse 
models remain the gold standard to evaluate CSCs, in vitro assays have also been 
developed to assess the clonogenic potential of CSCs including colony formation in semi-
solid media or tumor sphere formation in liquid culture.  Moreover, these in vitro assays 
may quantify the number of cells with self-renewal and long-term growth potential 
through serial rounds of plating.   
 Candidate CSC markers have largely consisted of differentially expressed cell 
surface antigens or drug resistance pathways.  One approach to identify novel CSC 
populations has been the use of surface antigens expressed by normal stem cells in the 
tissue of origin, such as CD34 in myeloid leukemias (3, 17).  Alternatively, antigens or 
enzymes capable of identifying normal stem cells in multiple tissues, such as CD133 and 
Aldehyde dehydrogenase (ALDH), have also been used to isolate CSCs in several 
diseases (18-22).  Additionally, specific antigens associated with poor prognosis, such as 
CD44 or c-Met, have also served as CSC markers (5, 23-25).  Finally, recent work makes 
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use of distinct metabolic features of CSCs, such as riboflavin accumulation, in order to 
isolate them (8). 
The initial identification of pancreatic CSCs extended ground-breaking work in 
breast cancer and investigated the expression of CD44, CD24, and epithelial specific 
antigen (ESA) (Table 1) (5, 14).  Relative to unsorted cells, CD44+CD24+ESA+ cells 
isolated from low-passage PDAC xenografts were highly tumorigenic and recapitulated 
the histology and cellular heterogeneity of the original tumor.  Furthermore, the 
functional differences between CD44+CD24+ESA+ and CD44-CD24-ESA- cells were 
maintained following subcutaneous or orthotopic injection suggesting that tumorigenic 
potential was cell autonomous and independent of local environmental factors.  A second 
report demonstrated that CD133 could also identify pancreatic CSCs (7).  In addition to 
being highly tumorigenic, CD133+ pancreatic cancer cells were found to be relatively 
resistant to gemcitabine treatment compared to CD133- cells.   
Cellular markers associated with drug resistance have also been used to identify 
CSCs.  ALDH, specifically ALDH1A1, is required for the synthesis of all-trans-retinoic 
and high enzyme activity marks normal mouse pancreatic progenitor cells and normal 
human stem cells in several organ systems (26, 27).  ALDH may also play a role in drug 
resistance as it can metabolize and neutralize specific cytotoxic alkylators, such as 
cyclophosphamide.  We studied ALDH in PDAC and found that ALDH+ cells are highly 
tumorigenic compared to bulk tumor cells (6, 28).  Moreover, ALDH+ cells appear to be 
relatively resistant to gemcitabine in vivo and have increased invasive potential 
suggesting a role in disease progression (6, 13).   
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Despite the importance of CD44, CD133, and ALDH in identifying pancreatic 
CSCs, it is unclear whether these antigens are involved in regulating CSC function or 
merely serve as phenotypic markers.  However, other pancreatic CSC markers have been 
identified that may be functionally relevant.  For example, CXCR4 serves as the 
chemokine receptor for Stromal cell-derived factor-1 (SDF-1, CXCL12) and is expressed 
by a subset of CD133+ CSCs that have enhanced metastatic capacity (7).  Recent studies 
have also demonstrated that c-Met can identify and regulate pancreatic CSCs similar to 
findings in glioblastoma (25, 29).  Thus, several strategies have been used to identify 
pancreatic CSCs, and some of these may provide insights into regulatory factors and 
potential targeting strategies. 
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Figures and tables  
 
Table 1(14).  Phenotype and functional properties of pancreatic CSC populations.	
Study Phenotype Properties 
Li et al.(30) CD44+CD24+ESA+ Increased Sonic Hedgehog 
expression. 
Hermann et al.(7) CD133+ Chemoresistant. 
CD133+CXCR4+ cells 
responsible for metastasis. 
Rasheed et al.(31) 
Ishizawa et al.(28) 
ALDH+ CSCs associated with 
overall survival.  CSCs 
exhibit mesenchymal 
feature and are frequently 
found in metastatic lesions.  
ALDH+ and CD44+CD24+ 
cells are equally 
tumorigenic. 
Li et al.(25) CD44+c-Met+ Highly metastatic. 

























The relationship between distinct 
























 In most normal organ systems, such as the blood, CNS, and skin, cells are 
functionally and phenotypically organized according to a strict cellular hierarchy in 
which self-renewing stem cells give rise to short lived progenitors then terminally 
differentiated effector cells.  The earliest studies in acute myeloid leukemia (AML) 
demonstrated that tumor cells resembling normal hematopoietic stem cells can self-renew 
and give rise to relatively differentiated and non-tumorigenic blasts (4).  Therefore, it has 
been generally assumed that cancers are organized in a hierarchical manner similar to 
normal tissues.  However, several CSC populations have been identified in PDAC, and it 
is not clear how each of these fits into a specific hierarchy or are related to one another.  
One possibility is that all of the current markers recognize the same cell, but the vast 
majority of ALDH+ pancreatic tumor cells appear to lack CD44 and CD133.  Therefore, 
it is likely that these antigens identify at least two, or even three, unique cell populations 
(6, 32).  Alternatively, since each putative CSC marker enriches for cells with increased 
tumorigenic potential but fails to isolate pure populations of CSCs (i.e., every cell 
expressing a specific marker is not tumorigenic), it is possible that combining antigens 
will greatly increase CSC purity.  However, this does not appear to be the case as the 
tumor initiating cell frequency of rare PDAC cells co-expressing CD44, CD24, and 
ALDH is not significantly greater than either ALDH+ or CD44+CD24+ cells (28).  
Moreover, c-Met is expressed, albeit at variable levels, on CD44+, CD133+, or ALDH+ 
cells, but increased tumorigenic potential is limited to CD44+c-Methigh cells (25). 
Delineating the relationship between these populations is a critical step in the 
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development of successful therapies since all self-renewing cells within a pancreatic 
tumor must be targeted and eliminated. Therefore, we tested whether pancreatic 
adenocarcinoma cells are organized as a hierarchical system with a phenotypically 











































 Capan-1 cells were obtained from the American Type Culture Collection 
(Manassas, VA) global bio-resource center and authenticated by short tandem repeat 
profiling at the Johns Hopkins Genetics Core Resources Facility.  Cells were cultured in 
high glucose Dulbecco’s modified Eagle medium (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO), 1% 
penicillin-streptomycin (Invitrogen), and1% L-glutamine (Invitrogen).  Cells were 
cultured in normal 35-mm culture dishes (Corning, Corning, NY), and normal 25cm2, and 
75cm2 tissue culture flasks (Sarstedt, Nümbrecht, Germany). 
 
Animal care and patient derived xenografts  
 
 All experiments using mice were approved by the Johns Hopkins University 
Animal Care and Use Committee and the mice were maintained in accordance with the 
American Association of Laboratory Animal Care guidelines.  Low passage xenografts 
were generated of surgical specimens derived from patients undergoing surgery at the 
Johns Hopkins Hospital.  Freshly collected tumors were implanted subcutaneously into 6-
week-old female athymic nude mice (Harlan), and following growth to 1.5 cm3 they were 
excised and transplanted to secondary recipients. 
 To generate cell line and patient xenogratfts we resuspended cells in serum-free 
DMEM and Matrigel (BD Biosciences, San Jose, CA) in a 1:1 ratio and then injected 
them (in 100 µL volume) subcutaneously into the flanks of NOD/SCID mice lacking the 
interleukin-2 receptor gamma chain (NSG).   
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Flow cytometry and cell sorting 
 Single cell suspensions from cell line-derived and patient-derived xenografts were 
prepared by mincing tumors using sterile razor blades, followed by mechanical and 
enzymatic dissociation using the MACS Dissociation Kit (Miltenyi Biotec, San Diego, 
CA) (cite).  Tumor debris and necrotic cells were depleted using a 70-µm filter (BD 
Biosciences) and density centrifugation using Ficoll-Paque Plus (GE Healthcare, 
Marlborough, MA).   
 Cells were then stained with the ALDEFLUOR reagent (Stem Cell Technologies, 
Vancouver, Canada) for 30 minutes in a 37°C water bath according to the manufacturer’s 
protocol.  Next they were stained for 15 min at 4°C with anti-mouse CD31-biotin (BD 
Biosciences), anti-mouse lineage-biotin (Miltenyi Biotec), and anti-mouse H-2Kd-biotin 
(BD Biosciences) antibodies.  They were then washed, and stained for 15 min at 4°C with 
Streptavidin–PerCP (BD Biosciences), followed by a wash and a staining at 4°C for 20 
min with anti-CD44-APC (clone G44-26, BD Biosciences) and anti-CD24-PE (clone 
ML5, BD Biosciences).  A FACSAria II Flow Cytometer (BD Biosciences) and BD 
















Tumors derived from distinct CSCs, and non-CSCs exhibit identical phenotypic 
composition 
 
 In order to study the relationship of distinct CSC populations, we injected Capan-
1 cells subcutaneously into the flanks of NSG mice and allowed tumors to develop for 
three weeks.  These tumors were then collected, sorted into non-overlapping 
CD24+CD44+ and ALDH+ cells, and cells that did not express any of these markers, and 
injected into the flanks of NSG (Fig 1). After six weeks the resulting tumors were 
examined for the presence of different phenotypic populations by flow cytometry.  
Interestingly, the cellular diversity characteristic of the original tumors was present in the 
tumors derived from each sub-population (Fig 2a).  We also studied patient derived 
pancreatic cancer tumors continuously passaged in immune deficient mice (xenografts) 
that have been extensively studied by full exomic sequencing and gene expression 
profiling6.  We used these tumors in order to capture the biology of pancreatic cancer that 
occurs in the clinical setting and more precisely examine the relationship between distinct 
cancer stem cell populations.  We grew Panc219 tumors subcutaneously in NSG mice 
and isolated CD24+CD44+ and ALDH+ cells, and cells that did not express any of these 
markers.  Eight weeks after we injected the sorted cells we looked for the presence of 
different populations by flow cytometry.  Regardless of their origin, the tumors exhibited 
striking similarity (Fig 2b).  Thus multiple non-overlapping cell populations can 






 We have demonstrated that two distinct largely non-overlapping CSC populations 
(CD24+CD44+ and ALDH+ cells) derived from pancreatic both cancer cell lines and 
patient derived sample can recapitulate the original phenotypic diversity in an in vivo 
setting.  Importantly cells that did not express these CSC markers were able to do so, as 
well.  Our results demonstrate that CD24+CD44+ and ALDH+populations might not 
display a hierarchical relationship but can give rise to one another.  Interestingly our data 
suggests that cells lacking these markers could also generate cancer stem cells.  Therefore, 
we now believe that the cellular organization of pancreatic cancers could be characterized 
by a high degree of plasticity. 
 The significance of the various pancreatic CSC markers and the cells they identify 
clearly requires further clarification (14).  If multiple CSC populations actually exist, an 
understanding of how they are related to one another will be important since clinically 
effective targeting likely requires the elimination of all self-renewing cells within the 
tumor.  It is still PDAC cells are organized in a hierarchical and linear manner with a 
single, phenotypically distinct, still unidentified, CSC, at the apex giving rise to the other 
CSC populations and ultimately non-clonogenic mature tumor cells (Figure 3) (14).  It is 
also possible that each phenotypically distinct CSC population represents a specific 
cellular state of the same clonogenic cell that gives rise to mature tumor cells.  Another 
possibility is that each CSC population is unrelated to another and parallel lines of mature 
tumor cell production exist.  Finally, it is conceivable that a rigid hierarchy of 
unidirectional differentiation does not exist, but that the system is plastic with non-
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clonogenic cells giving rise to tumorigenic CSCs displaying a variety of phenotypes. 
 Beyond the organization of phenotypically defined CSC populations, it is also 
unclear whether the various CSCs are functionally similar or distinct.  Although tumor 
formation, histologic recapitulation, and self-renewal define CSCs, other properties, 
including relative drug resistance, invasion, migration, and metastatic potential have been 
ascribed to CSCs and may contribute to their clinical impact (33).  It is possible that 
certain CSC populations could be primarily responsible for tumor initiation and 
maintenance at the primary site of disease, whereas others could be responsible for tumor 
dissemination and growth at metastatic sites, such as the subpopulation of CD133+ CSCs 
expressing CXCR4 (7).  It is also possible different organs, such as the liver and lung, 
harbor different microenvironments with distinct endothelial or stromal cell types or 
extracellular matrix components that promote or inhibit tumor growth (Figure 4) (34).  
Therefore, if metastatic dissemination depends on the interaction of CSCs with a 
particular niche, then different niches might call for unique CSCs.  An evaluation of the 
tumor forming potential of specific CSCs at orthotropic and different metastatic sites may 
determine whether certain populations are better suited to grow within particular 
locations. 
 It is also possible that the phenotypes exhibited by CSCs are dictated by the 
external microenvironment.  For example, pancreatic tumors are characterized by 
desmoplasia and dense fibrosis that may expose cells to relative hypoxia, and the hypoxic 
state has been found to alter the expression of the CSC marker CD133 in brain tumors 
(35).  In addition, several markers used to identify CSCs, such as ALDH and the side 
population assay, are indicative of drug resistance mechanisms and it is possible that their 
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expression is induced in response to cellular damage.  Finally, it is possible that the 
adaptive metabolic changes undertaken by tumor cells also modifies the expression of 
CSC makers, although such findings have yet to be reported (36). 
Studies have demonstrated a clear link between CSCs and the epithelial-to-
mesenchymal transition (EMT) in solid tumors.  Therefore, it is possible that CSCs 
represent a specific cellular state expressing multiple phenotypes.  Reports using breast 
cancer models have demonstrated that the induction of EMT by TGF-β or the modulation 
of specific gene expression (e.g., induction of Twist or repression of E-Cadherin) results 
in increased expression of CD44 and tumorigenic potential (37, 38).  In pancreatic cancer, 
ALDH+ cells appear have a gene expression profile consistent with EMT and increased 
invasive and migratory potential compared to bulk tumor cells and CD44+CD24+ cells (6).  
Moreover, studies examining ZEB1, an inducer of EMT, in pancreatic cancer cells have 
identified a direct link between EMT, increased tumorigenicity, and drug resistance (39).  
Therefore, it is possible that a more “epithelial” or “mesenchymal” state is important in 
determining the functional properties of CSCs.  The specific functional properties of 
different pancreatic CSCs are unclear, and the quantification of tumor formation, 
metastatic potential, and drug resistance is needed. 
Inter-patient heterogeneity may also contribute to the existence of multiple 
pancreatic CSCs.  Recurrent genetic alterations are a hallmark of cancer, and mutations in 
KRas are present in the vast majority of PDAC (40, 41).  On the other hand, mutations in 
other genes, such as p53 and Smad4/DPC4, can be identified in some, but not all tumors 
(42, 43).  Therefore, pancreatic cancers are not genetically homogeneous, but vary from 
patient to patient (44).  If alterations in specific genes are prognostic and CSCs truly 
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dictate the natural history of PDAC given their potential roles in tumor formation, drug 
resistance, and metastatic progression, it is likely that specific mutations influence both 
the phenotype and function of CSCs.  Currently, it is unclear whether phenotypically 
identical CSCs from different patients have the same functional attributes and contribute 
to disease progression in similar ways.  However, such a finding would imply that 
personalized and individualized CSC targeting therapies are needed.  In order to examine 
inter-patient diversity, the functional properties of different CSCs derived from human 
tumors with distinct genotypes will need to be determined.  In addition, the examination 
of CSC phenotypes and functional properties in tumors derived from transgenic animal 
models of pancreatic cancer may be particularly helpful since specific genetic lesions can 
be modulated in these systems (45). 
To further complicate matters, increasing evidence suggest that human cancers 
can be genetically heterogeneous within the same individual (46-49).  Therefore, intra-
patient genetic heterogeneity may also drive the phenotypic and functional diversification 
CSCs.  In many cancers, including PDAC, specific genetic alternations may accumulate 
in an orderly fashion during disease progression (50, 51), Thus, it is also possible that 
different CSCs are responsible for relapse and progression over the course of the disease.  
In PDAC, metastatic lesions may be genetically distinct from one another and the 
primary tumor (52).  Moreover, primary tumors are composed of geographically and 
genetically distinct subclones.  The role of genetic evolution and diversification in the 
emergence of distinct CSCs, or conversely, the impact of CSCs on the clonal composition 
of an individual tumor is not entirely clear, but it is likely that these two processes 
interact at some level.  Therefore, pancreatic CSCs may be phenotypically and 
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functionally distinct at specific anatomical sites or at each stage of clinical disease.  A 
systematic investigation of genetic lesions within CSCs, their phenotypes, and functional 
properties, such as tumorigenic potential, metastasis, and drug resistance, within primary 














Figure 1. Experimental design. Human xenografts were sorted based on cell surface 
expression of CD24 and CD44, and activity of Aldehyde dehydrogenase (ALDH). 
Secondary xenografts were generated from the sorted populations and their phenotypic 
diversity was examined by flow cytometry. 
 
Figure 2. Phenotypic plasticity between CSCs and non-CSCs. Tumors derived from 
sorted Capan-1 (A) or Panc 253 (B) xenografts exhibit identical phenotypic composition 
regardless of the cell of origin. 
 
Figure 3. Potential relationships between CSCs and mature tumor cells. (A) A linear 
organization with a single phenotypically distinct CSC giving rise to the other CSC 
populations and ultimately non-clonogenic mature cells.  (B) Each phenotypic CSC 
represents a distinct state of the same clonogenic cell that gives rise to the mature tumor 
cell.  (C) Each CSC population is unrelated to another and parallel lines of mature tumor 
cell production exist.  (D) A plastic system in which non-clonogenic mature cells give 
rise to CSC displaying a variety of phenotypes. 
 
Figure 4. Potential functional relationships between CSCs.  (A) Distinct CSCs may 
give rise to macroscopic tumors in distinct anatomical locations.  Each population is 
responsible for tumor growth and resistance to therapy in different organs.  (B) A primary 
CSC population is responsible for tumor initiation and growth at the primary site.  
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Additional populations are responsible for initiation and maintenance at metastatic sites 
and for resistance to chemotherapy.  





























































Regulation of cancer stem cell 










The self-renewal potential and resistance to traditional cytotoxic agents suggest 
that successful CSC targeting strategies will improve clinical outcomes.  One potential 
approach is targeting the cell surface antigens that characterize pancreatic CSCs using 
monoclonal antibodies.  For example, a bi-specific antibody recognizing both ESA and 
CD3 has been found to eliminate pancreatic CSCs by redirecting cytotoxic T-
lymphocytes (53).  CD44 is another surface protein expressed by CSCs in multiple 
diseases (54), and a specific monoclonal antibody against CD44 can eliminate AML stem 
cells by inducing terminal differentiation (55).  The functional activities of specific 
pancreatic CSC markers may also serve as potential targets (Table 1).  The hepatocyte 
growth factor (HGF) receptor c-Met identifies highly tumorigenic CSCs in combination 
with CD44, and the pharmacological inhibition of its activity has been found to inhibit 
tumor growth and metastasis (25).  CD47 is expressed preferentially on CD133+ cells and 
normally protects them from being phagocytosed by macrophages (56).  Inhibition of 
CD47 enhances phagocytosis of CSCs and also directly induces their apoptosis.  Another 
functionally relevant marker is CXCR4 that plays an important role in the homing of 
hematopoietic stem cells to the bone marrow.  CXCR4 has been identified on a subset of 
CD133+ pancreatic CSCs with enhanced metastatic capacity, and CXCR4 antagonists 
may prevent tumor dissemination (7).  Another potential cell surface target is Death 
receptor 5 (DR5) that induces apoptosis following binding to TRAIL.  A recent study 
found that ALDH+ and CD44+CD24+ pancreatic CSCs express relatively increased levels 
of DR5, and receptor engagement using an agonistic monoclonal antibody markedly 
reduced CSC frequency and tumor growth in vivo (57). 
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Several cellular signaling pathways have been identified that regulate the self-
renewal of normal stem cells and may serve as targets against CSCs.  These include 
pathways required for normal embryonic development, and the Hedgehog (Hh), Notch, 
and Nodal/Activin pathways may be active in pancreatic CSCs.  Nodal and Activin are 
ligands of the TGF-β superfamily, and a recent study demonstrated that these ligands and 
their receptor ALK4 are overexpressed in pancreatic CSCs (58).  The pharmacological 
inhibition or knockdown of ALK4 abrogated self-renewal and tumorigenicity as well as 
sensitized CSCs to gemcitabine.  Another series of studies has examined the Hh signaling 
pathway in pancreatic CSCs and found that pharmacological pathway inhibition reduced 
the frequency of CSCs and decreased tumor formation and metastasis (13, 59, 60).  Of 
note, a recent phase 2 clinical trial compared gemcitabine alone or in combination with 
the novel Hh inhibitor saridegib (IPI-926) in patients with metastatic pancreatic cancer 
based on preclinical data demonstrating enhanced responses to cytotoxic chemotherapy 
(61).  A higher rate of progressive disease was observed at an interim analysis in patients 
receiving saridegib (http://phx.corporate-ir.net/phoenix.zhtml?c=121941&p=irol-
newsArticle&ID=1653550&highlight=).  Although the precise reasons for these results 
are unclear, it is possible that the Hh pathway regulates the development, rather than 
maintenance, of metastatic lesions and other ongoing trials of Hh inhibitors in the 
neoadjuvant setting may provide a better scenario to detect these potential anti-CSC 
effects.  Finally, the inhibition of Notch signaling has been found to inhibit EMT and 
cellular invasion as well as decrease the frequency of ALDH+ CSCs (62).  Thus, cellular 
pathways involved in regulating the self-renewal of normal stem cells may represent 
pancreatic CSC targets.  
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Differential metabolic requirements of CSCs can also serve as a method for 
targeting them.  PDAC CSCs are dependent on oxdative phosphorylation (OXPHOS), 
and can have very limited metabolic plasticity(63).  The anti-diabetic drug metformin 
decreases tumor growth and initiation.  Combining metformin with the bromodomain 
family of proteins inhibitor JQ1 targets CSCs and prevents the emergence of metformin 
resistant clones. 
 The association of EMT and CSCs may also form the basis for identifying novel 
targeting agents.  High-throughput strategies to screen for novel anti-CSC compounds 
have been difficult to carry out because of the lack of pure CSC populations and the 
complex nature of the assays used to assess their functions, but several methods may 
induce EMT and increase the frequency of CSCs.  This approach was ingeniously used 
by Gupta et al. who genetically engineered human breast cancer cell lines to induce EMT 
and screened for compounds that could induce cell death (37).  The ionophore 
salinomycin was identified as a potential CSC targeting agent then subsequently found to 
block tumor formation and metastasis in vivo.  Shortly thereafter, salinomycin was shown 
to inhibit the growth of pancreatic CSCs, indicating that it may represent a potential CSC 
targeting agent in multiple malignancies (64).  Therefore, similar strategies based on 
EMT may identify novel agents that inhibit pancreatic CSCs.  
 Strategies eliminating one or two specific CSC populations might have a limited 
success since a successful treatment would need to eradicate all sources of self-renewal 
within the tumor.  It is critical to determine whether there are fundamental processes that 
regulate CSC functions, regardless of the underlying phenotype.  Targeting multiple 
populations is more likely to improve disease outcome.  
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 An area of investigation that has gained increased interest over the past ten years 
is the regulation of cell fate commitment by actin dynamics.  In several contexts changes 
in cell shape dictate differentiation decisions (65-71).  The driver of these cell shape 
induced decisions is a shift in actin polymerization dynamics. Keratinocyte 
differentiation is regulated by the balance between polymerized (F-actin) and free actin 
(G-actin), where a lower F/G actin ratio drives stem cell maintenance (65).  In embryonic 
stem cells (ESCs) a blockade of actin polymerization leads to the maintenance of self-
renewal and negates the need of Leukemia Inhibiting Factor (LIF) to maintain the cells in 
an undifferentiated state (67).  In the case of mesenchymal stem cells (MSCs), actin 
dynamics determine osteogenic versus adipogenic differentiation (69). Furthermore, 
changes in actin polymerization and organization in MSCs can override soluble 
differentiation signals (69).  Given that regulation of differentiation by modulation of 
actin dynamics is a mechanism present in multiple systems we hypothesized that it is also 
active in the maintenance of CSCs. 
 When we were devising a strategy to study the biology of actin polymerization 
and organization in CSCs we wanted to find a reliable method to examine these 
characteristics.  Additionally, it was our desire to find a way to target the processes 
pharmacologically in order to explore potential therapeutic strategies.  We decided to 
investigate actin dynamics in CSCs by modulating the expression and activation of the 
membrane-actin linker protein Ezrin. 
 Ezrin is a member of the Ezrin-Radixin-Moesin (ERM) family of proteins that 
function by connecting molecules on the plasma membrane to the actin cytoskeleton (72-
74).  Ezrin is kept inactive in the cytoplasm by a head-to-tail interaction between its N-
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terminus and C-terminus.  Upon activation and interaction with PIP2, Ezrin assumes an 
unfolded conformation that allows phosphorylation of a threonine residue at position 567 
in its C-terminus.  This phosphorylation is necessary for Ezrin to bind to actin filaments 
with its C-terminal domain.  With its N-terminal FERM domain the protein binds cell 
surface receptors or channels through their cytoplasmic tails or through adaptor proteins.  
 Modulation of Ezrin expression or activity alters cell shape and actin filament 
organization in multiple systems (75-79).  Additionally, Ezrin can be found in a complex 
with two of the cell surface markers used to identify PDAC CSCs as its N-terminal 
domain Ezrin binds to the cytoplasmic tail of CD44 (80).  Ezrin is also a substrate for the 
receptor tyrosine kinase HGF/c-Met and its association with CD44 is necessary for c-
Met-mediated signal transduction (81-83).  Thus Ezrin suggested a potential link between 
CSC associated surface antigens and cytoskeletal dynamics. 
 Recently, we have identified a pharmacological agent (Drug 8) that inhibits Ezrin-
actin interaction (84).  Additionally, the levels of Ezrin expression or activation are a 
predictor of decreased survival or the development of distant metastases in multiple 
cancers, indicating its importance in tumor biology (85-92).  In PDAC the expression 
levels of Ezrin itself do not correlate with negative outcomes, however, phosphorylation 
of Ezrin, associated with growth factor receptor activation predicts shorter overall 
survival (93-95).  Experiments in PDAC cell lines indicate that Ezrin mediates growth 
and motility, but its role in cytoskeletal remodeling and CSC biology has not been 
investigated (96, 97).  Thus we chose Ezrin as both a tool to study the role of actin 
dynamics in CSC biology and a potential therapeutic target. 
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  Our studies identified modulation of actin dynamics as a novel mechanism of 
regulation of CSC functions. In PDAC, Ezrin maintains a CSC-associated actin state, at 





 L3.6pl, E3LZ 10.7, and MIA PaCa-2 cells were obtained from the American Type 
Culture Collection (Manassas, VA) global bio-resource center and authenticated by short 
tandem repeat profiling at the Johns Hopkins Genetics Core Resources Facility.  All cell 
lines were cultured in high glucose Dulbecco’s modified Eagle medium (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, 
MO), 1% penicillin-streptomycin (Invitrogen), and1% L-glutamine (Invitrogen).  Cells 
were cultured in normal 35-mm culture dishes (Corning, Corning, NY), and 25cm2, and 
75cm2 normal tissue culture flasks (Sarstedt, Nümbrecht, Germany) 
 An siRNA sequence against Ezrin was obtained from GE Dharmacon (Lafayette, 
CO; siRNA1 cat. #: NM001111077).  A short hairpin RNA (shRNA) oligonucleotide was 
generated from this sequence and cloned into the Tet-pLKO-puro lentiviral vector 
(Addgene, Cambridge, MA).  An shRNA sequence against the Luciferase gene was used 
as a control construct. Cell lines were transduced and stable lines were selected using 
puromycin (Thermo Fisher Scientific, Waltham, MA). 
 A complementary DNA (cDNA) sequence of Ezrin, containing a threonine to 
aspartic acid substitution at residue 567 was obtained from Aykut Uren’s laboratory at 
Georgetown University (Washington, DC).  The cDNA was cloned into the pInucer20 
lentiviral vector using the Gateway cloning system (Thermo Fisher Scientific) (98). A 
self-ligated empty pInducer20 construct was used as a control. Cell lines were transduced 
and stable lines were selected using G418 sulfate (Corning). 
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Animal care, low passage derived patient xenografts, and tumorspheres 
 All experiments using mice were approved by the Johns Hopkins University 
Animal Care and Use Committee and the mice were maintained in accordance with the 
American Association of Laboratory Animal Care guidelines.  Low passage xenografts 
were generated of surgical specimens derived from patients undergoing surgery at the 
Johns Hopkins Hospital.  Freshly collected tumors were implanted subcutaneously into 6-
week-old female athymic nude mice (Harlan), and following growth to 1.5 cm3 they were 
excised and transplanted to secondary recipients. 
 Single cell suspensions from patient-derived xenografts were prepared by mincing 
tumors using sterile razor blades, followed by mechanical and enzymatic dissociation 
using the MACS Dissociation Kit (Miltenyi Biotec, San Diego, CA) (31).  Tumor debris 
and necrotic cells were depleted using a 70-µm filter (BD Biosciences) and density 
centrifugation using Ficoll-Paque Plus (GE Healthcare, Marlborough, MA).  Cells were 
then labeled using anti-mouse CD31-biotin (BD Biosciences), anti-mouse lineage-biotin 
(Miltenyi Biotec), and anti-mouse H-2Kd-biotin (BD Biosciences) antibodies, followed 
by incubation with ant-biotin-coupled magnetic microbeads (Miltenyi Biotec).  Mouse-
derived cells were depleted using a MACS Cell Separation LD Column (Miltenyi Biotec).  
Cells were washed twice in cold phosphate buffer saline (PBS) (Invitrogen) and manually 
counted using a hemocytometer.   
 For generation of tumorspheres, 200,000 cells/ml were plated in DMEM/F-12 
(1/1) media (Invitrogen) supplemented with 1X B-27 supplement (Thermo Fisher 
Scientific), 20ng/ml bFGF (Invitrogen), 1% penicillin-streptomycin (Invitrogen), and 1% 
L-glutamine (Invitrogen).  Cells were cultured in 60-mm ultralow attachment tissue 
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culture dishes (Corning).  After 7-10 days spheres were selected by washing trough a 40-
µm Filter (BD Biosciences).  They were then dissociated enzymatically with 0.05% 
Trypsin (Invitrogen) and plated at 2*103 cells/ml for differentiation studies or 1*104 
cells/ml for Drug8 treatments or maintenance of spheres. 
 
In vivo limiting dilution assay 
 To measure tumor-initiating cell frequency (TIF), we resuspended 100,000 L3.6pl 
cells containing the Tet-pLKO-puro construct in serum-free DMEM and Matrigel (BD 
Biosciences) in a 1:1 ratio and then injected them (in 100-µL volume) subcutaneously 
into the flanks of NOD/SCID mice lacking the interleukin-2 receptor gamma chain 
(NSG).  The tumors were allowed to grow until a volume of approximately 100mm3 after 
which their drinking water was substituted for 2mg/ml of Doxycycline (Sigma-Aldrich) 
in 5% sucrose solution (Sigma-Aldrich).  Control mice from both groups received only a 
5% Sucrose solution (Sigma-Aldrich).  Tumors were measured after 3, 6, and 9 days in 2 
perpendicular dimensions and tumor volume was calculated using the formula for prolate 
ellipsoid: mm3= (L x W2)/2. After 9 days of treatment the tumors were collected, 
dissociated, and depleted from mouse cells according to protocol.  They were washed in 
cold serum-free DMEM twice, and manually counted using a hemacytometer.  Next they 
were resuspended in serum-free DMEM and Matrigel (BD Biosciences) in a 1:1 ratio and 
then injected (in 100µl volume) subcutaneously in the flanks of NSG mice in limiting 
dilutions (500, 250, 100, 50 cells).  Mice were monitored for tumor formation for 30 days. 




 Cells from patient derived xenografts were stained for 15 min at 4°C with anti-
mouse CD31-biotin (BD Biosciences), anti-mouse lineage-biotin (Miltenyi Biotec), and 
anti-mouse H-2Kd-biotin (BD Biosciences) antibodies.  They were then washed, and 
stained for 15 min at 4°C with Streptavidin–PerCP (BD Biosciences), followed by a wash 
and a staining at 4°C for 20 min with anti-CD44-APC (clone G44-26, BD Biosciences), 
anti-CD24-PE/FITC (clone ML5, BD Biosciences), anti-c-Met-PE (clone 95106, R&D 
Systems, Minneapolis, MN), and anti CD133-APC (Clone AC133, Milteniy Biotec). 
 For intracellular staining, cells were fixed and permeabilized for 30 min at 4°C 
with Cytofix/Cytoperm buffer (BD Biosciences).  They were washed and incubated in 
5% Bovine Serum Albumin (BSA) and 2mM EDTA in PBS for 1hr at room temperature. 
Then they were washed and stained for 1 hour at room temperature in the dark with rabbit 
polyclonal anti-Ezrin (Cell signaling, Danvers, MA, 1:50 dilution), rabbit polyclonal anti-
pERM (Cell signaling, 1:1000 dilution), phalloidin-TRITC/FITC (Sigma-Aldrich, 125 
ng/ml), and DNAse1-AlexaFluor488 (Sigma-Aldrich, 500 ng/ml) in 0.5% BSA and 2mM 
EDTA in PBS.  Cells were washed and then incubated with goat anti-rabbit-
AlexaFluor488 (Invitrogen, 1:1000 dilution) for 1 hr at room temperature in the dark.  
They were then washed and a BD FACScalibur (BD Biosciences) was used for analysis. 
 Cells from cell lines and tumorspheres were not labeled with with anti-mouse 
CD31-biotin (BD Biosciences), anti-mouse lineage-biotin (Miltenyi Biotec), and anti-
mouse H-2Kd-biotin (BD Biosciences) antibodies.  They were stained with the rest of the 
antibodies according to protocol. 
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Quantitative real-time PCR analysis 
 Total mRNA was extracted using and depleted of genomic DNA using the 
RNeasy PlusMini Kit (Qiagen, Germantown, MD).  It was reverse-transcribed with 
SuperScript III reverse transcriptase (Invitrogen). qRT-PCR was performed using 
Taqman Probes (GAPDH probe #: hs099999905, Ezrin probe #:hs00931653) (Applied 
Biosystems, Foster City, CA).  
 
Colony formation assay 
 One thousand cells were suspended in 1ml of 1.2% methylcellulose (Sigma-
Aldrich), 30% fetal bovine serum (Sigma-Aldrich), 1 %BSA (Sigma-Aldrich), 1% 
penicillin-streptomycin (Invitrogen), 1% L-Glutamine (Invitrogen), and 10-4M 2-
mercaptoethanol in RPMI medium (Invitrogen).  Samples were plated in duplicate in 35-
mm ultralow attachment tissue culture dishes (Corning) and incubated at 37oC. Colonies 
were scored after 12-15 days.  Serial replating was carried out by washing the plates 3 
times with serum-free RPMI media, resuspending the cells in the original volume of 
methylcellulose, and re-plating according to protocol.  
 
Migration assay 
 Six hundred thousand (L3.6pl) or 200,000 (E3LZ 10.7, MIA PaCa-2) cells 
suspended in DMEM supplemented with 1% FBS were applied to 24-well cell culture 
inserts with 8-µm pores (BD Biosciences). The cell culture inserts were immersed in 
DMEM supplemented with 10% FBS. The cells were cultured at 37oC and 5% CO2, and 
after 24 hours the cells remaining above the filter were removed. The filter membrane 
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was removed and fixed onto a frosted microscope slide (Thermo Fisher Scientific), using 
ProLong Gold Antifade Reagent with DAPI (Life Technologies), and coverslipped with a 
microscope cover grass (Thermo Fisher Scientific). After 24 hours pictures of the slides 
were taken with a Nikon Eclipse Ti fluorescent microscope (Nikon, Minato, Tokyo, 
Japan). The number of DAPI nuclei in three random fields from each slide was calculated 
using the NIS Elements software (Nikon).  
 
Immune fluorescence 
 Cell lines were grown on on LAB-Tek II 4-well glass slides (Thermo Fisher 
Scientific).  Prior to staining cells were washed with PBS three times and fixed with 4% 
Formalin for 15 min at room temperature, after which they were washed 10 times with 
PBS.  After fixation they were incubated in 5% BSA and 0.3% Triton-X (Sigma-Aldrich) 
in PBS for 1 hour at room temperature. The buffer was aspirated and the cells were 
stained in 1%BSA and 0.3% in Triton-X PBS with Phalloidin-TRITC (Sigma-Aldrich, 
125ng/ml) and DNAse1-Alexafluor488 (Sigma-Aldrich, 10ug/ml) for 1 hr at room 
temperature in the dark.  Then cells were washed 10 times with PBS and coverslipped 
with a microscope cover grass (Termo Fisher Scientific) using Prolong Gold Antifade 
reagent with DAPI (Life Technologies). Pictures were taken with a Nikon Eclipse Ti 
fluorescent microscope (Nikon) using the NIS Elements software (Nikon). 
 Tumorspheres were collected and suspended in 250uL PBS then fixed on glass 
Shendon cytospin slides (Thermo Fisher Scientific) by centrufugation in a Cytospin4 
centrifuge (Thermo Fisher Scientific) at 800rpm for 5 minutes.  They were then air-dried 
for 3 minutes and processed as described above. 
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Drug treatments 
 Compound NSC305787 (Drug 8) was obtained from Aykut Uren’s laboratory at 
Georgetown University (Washington, DC).  
 Cell lines were treated with 1uM of the drug for 72 hours in regular cell culture 
dishes after which they were collected by trypsinization and plated in a colony-forming 
assay in methylcellulose.  
 Tumorspheres were plated at a density of 10,000 cells/ml and after three days they 
were treated with 1uM of the compound. After an additional 72 hrs they were collected, 
enzymatically broken down to single cells and half of all remaining cells were suspended 
in 2ml media. The number of spheres formed after 7 days was scored.  
 Cytochalasin D (Tocris Biosciences, Bristol, United Kingdom) and Y-27632 
dihidrochloride (Sigma-Aldrich) were resuspended according to manufacturer’s protocol. 
Cell lines were treated with the compounds in regular cell culture dishes after which they 
were collected and plated as single cells in colony forming assay in methylcellulose. 
 
Statistics 
 Statistical differences between two normalized groups were analyzed using a one-
sample t-test (GraphPad Prism Software, Inc). Statistical differences between non-










CSCs exhibit distinct actin dynamics and organization 
 
 The balance between F-actin and G-actin can function to drive cell fate decisions 
such as the maintenance of stem cell status and self-renewal versus differentiation (65).  
To determine the F/G actin ratio, we carried out flow cytometry in CD24hiCD44hi CSCs 
vs. bulk tumor cells in low passage human xenografts.  Although CSC populations have a 
higher baseline expression of both F-actin and G-actin, we found that these cells exhibit a 
lower relative amount of polymerized actin (Fig 1a), reminiscent of undifferentiated 
keratinocyte progenitors. We also wanted to characterize the organization of actin in 
CSCs and differentiated cells. We grew the xenografts as spheres in FBS free media to 
expand the CSC populations (63, 100), then differentiated tumor.spheres by culturing 
them in FBS-containing sphere media.  To characterize the actin organization during 
CSC differentiation, we stained single cells with phalloidin and DNAse1 to visualize 
polymerized and free actin, respectively.  CSCs were rounder and exhibited punctate 
cortical F-actin staining and a strong G-actin staining pattern, with presence of G-actin in 
the nucleus (Fig 1b). This G-actin staining pattern is characteristic of undifferentiated 
keratinocyte progenitors (65).  In contrast, cells from differentiated spheres had a 
flattened morphology with a continuous cortical F-actin pattern and only a weak staining 
for G-actin. An increased amount of cortical is associated with the differentiation of 
MSCs towards the osteogenic lineage (70).  Therefore CSCs display actin cytoskeletal 
features characteristic of undifferentiated cells in several normal systems.  
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Ezrin regulates actin dynamics 
 We decided to use Ezrin as a tool to study cytoskeletal dynamics for several 
reasons.  Ezrin modulates cell shape and actin dynamics across multiple organisms. 
Additionally, Ezrin binds to the cytoplasmic tail of the CSC marker CD44, and this 
interaction is necessary for the signaling transduction cascade of another CSC marker, c-
Met.  We examined Ezrin expression in CSCs and differentiated tumor cells and found 
that CSCs from human xenografts and PDAC cell lines expressed higher amounts of 
Ezrin relative to non-CSCs (fig 2a).  Ezrin is activated by phopsphorylation after which it 
binds to actin and we found that CSCs express highel levels of pERM and actin binding 
(Fig 2a).  
 We knocked down Ezrin in L3.6pl cells using an inducible shRNA and found that 
loss of Ezrin increased cortical F-actin and the F/G actin ratio, decreased nuclear G-actin 
staining, and caused a flattened morphology, consistent with changes during CSC 
differentiation. (Fig 2b,c, Sup 1). Our findings indicate that Ezrin is a CSC associated 
protein and regulates actin dynamics.  
 
Ezrin regulates CSC functions 
 To determine the impact of Ezrin loss on functional properties we knocked down 
Ezrin for seven days in L3.6pl, E3LZ10.7, and MIA PaCa-2 cells.  Ezrin is a well-
documented regulator of motility in several malignancies, including pancreatic cancer (96, 
97).  As expected, the total number of migratory cells in all cell lines was decreased after 
7 days of Ezrin shRNA induction (fig. 3a, Sup 3). 
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 To quantify clonogenic growth potential we withdrew the doxycycline after 7 
days of doxycycline treatment and plated a proportion of the remaining cells in a semi-
solid colony formation media. Loss of Ezrin expression for 7 days resulted in a decrease 
in the total clonogenic output of the cells (Fig 3b. sup 3).  To quantify self-renewal, we 
serially re-plated the remaining colonies and found a decrease in the total clonogenic 
output over two serial replatings in all cell lines (Fig 3b, Sup 3).  Even though 
doxycycline administration was discontinued during colony formation, the cells never 
regained their ability to form colonies during the 28 days in colony formation media.  
When loss of Ezrin was induced over a period of 21 days, L3.6pl cells regained mRNA 
expression, however, they never recovered their self-renewal potential (Sup 2).  Our 
results indicate that the change in actin dynamics over 7 days led to a permanent loss of 
self-renewal potential. Moreover, at the end of the 7 day treatment there were no 
significant changes in the viability of L3.6pl cells (Fig 3c).  We also characterized the 
changes that occur earlier after Ezrin loss, and foud that 72 hours of doxycycline 
treatment did not significantly increase apoptosis (Fig 3c).  
 We wanted to know whether these changes could be due to a loss of CSC 
frequency.  When we assessed for CSCs by flow cytometry after 7 days of shRNA loss, 
we say a decrease in CD24+CD44+, CD44+cMet+ (Fig 3d).  Interestingly, although the 
cells did not express CD133, loss of Ezrin decreased the frequency of additional CSC 
phenotypes, such as ALDH+ cells (sup 2).  
 In order to determine the relationship between actin dynamics and clonogenic 
tumor growth we inhibited actin polymerization with CytochalasinD and Y-27632 in 
L3.6pl cells over period of 24 hours.  CytochalasindD disrupts F-actin filaments and 
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inhibits polymerization, whereas Y-27632 can indirectly lead to an increase in 
depolymerization (101-103).  We observed an increase in colony formation potential 
following treatment with both drugs (Sup 2).   
 We also expressed a constitutively active form of Ezrin with a threonine to 
aspartic acid substitution at residue 567 (t567d) in L3.6pl cells and observed increased 
Ezrin activation, accompanied by an increase in migratory cells, clonogenicity, and the 
frequency of CSCs (Fig 3 e, f, g, Sup 4).  
 
Loss of Ezrin expression diminishes in vitro tumorigenicity 
 CSCs are functionally defined by their enhanced tumor formation potential and 
we extended our in vitro findings by examining tumor formation in vivo.  We injected 
L3.6pl cells containing doxycycline inducible shRNA against Ezrin or a control shRNA 
subcutaneously into NSG mice, and following formation of primary tumors treated mice 
with doxycycline (fig 4a). During doxycycline treatment, there were no significant 
changes in tumor sizes, although, histologically loss of Ezrin resulted in more clusters of 
differentiation in the primary tumors  (Fig 4b,c).  We then collected tumors and re-
transplanted decreasing numbers of tumor cells into naïve recipients.  In the absence of 
additional doxycycline treatment, the tumor initiating frequency during secondary 
engraftment of cells carrying the Ezrin shRNA construct was significantly decreased 
compared to cells with the control shRNA (Table 2).  There were no differences in tumor 
growth and clonogenicity between the two groups when doxycycline was not 
administered (sup 5).  Thus, transient Ezrin knockdown impairs long-term clonogenic 
growth and self-renewal in vivo. 
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Pharmacological inhibition of Ezrin activity decreases the self-renewal capacity in 
human pancreatic cancer samples 
 Recently we identified several compounds that that inhibit the phosphorylation of 
Ezrin at threonine 567 and its interaction with actin (84).  These compounds blocked 
Ezrin-mediated invasion of cell monolayers and survival of osteosarcoma cells in a 
mouse lung-culture system.  We tested one of the compounds (Drug8) in PDAC cells and 
found that it inhibited the binding of Ezrin to actin and decreased both colony formation 
and migration of L3.6pl, E3Lz 10.7, and MIA PaCa-2 cells (Fig 5a, Sup 6).  We also 
treated tumor spheres generated from low passage tumor xenografts with Drug 8. In three 
distinct clinical specimens sphere formation was significantly inhibited (Fig 5b).  
Therefore, pharmacological inhibition of Ezrin may represent a novel strategy to target 
pancreatic CSCs. 
 
Ezrin regulates actin dynamics by antagonizing RhoA activity  
 Ezrin is an orthologue of the Drosophila Moesin, which maintains cellular 
morphology by antagonizing the activity of the small GTPase Rho (104).  In this context 
loss of Rho activity can rescue the defects associated with loss of Moesin completely.  In 
mammalian systems RhoA activity is increased with the loss Ezrin and inhibition of the 
GTPase rescues defects in neuritogenesis and axonal growth in cultured cortical neurons 
of Ezrin knockout mice (76, 105).  RhoA typically regulates actin polymerization through 
its effector Rho-associated protein kinase (ROCK), and ROCK activation leads to 
inhibition of actin depolymerization (102).  ROCK activity plays a role in both normal 
and cancer stem cell biology. In normal systems cell fate decision based on cell shape 
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changes are regulated by the balance of actin polymerization, and modulation of RhoA 
activity and ROCK signaling (65, 69).  Furthermore, inhibition of ROCK, leads to the 
expansion of colorectal cancer and glioblastoma CSCs (106, 107).  To determine whether 
in PDAC Ezrin maintains a CSC-associated actin state we inhibited ROCK signaling with 
Y-27632, a specific inhibitor that competes with ATP for binding to the enzyme’s 
catalytic site (103). 
 We knocked down Ezrin by shRNA, then treated with Y-27632 together with 
doxycycline for the remaining 48 hours, for a total of 72 hours.  ROCK inhibition 
blocked the loss of clonogenicity, induced by Ezrin knockdown (Fig 6b).  Thus Ezrin 
















 Our results identify actin polymerization and organization as a novel mechanism 
for the regulation of CSCs.  There are numerous mechanisms through which this process 
could occur.  The balance between free and polymerized actin can influence 
transcriptional activity by regulating the availability of different co-factors (65).  
Presumably CSCs are able to self –renew and generate the bulk of the tumor by 
undergoing asymmetrical divisions.  Cytoskeletal changes could regulate the balance 
between symmetric and asymmetric divisions by controlling cellular polarity (108).  
Alternatively, actin dynamics could serve to organize different membrane domains, and 
thus modulate activity of various cell surface receptors (109, 110).  A further examination 
of the mechanisms of CSC regulation by the cytoskeleton would yield more targets for 
therapeutic intervention. 
 Small molecules that directly bind to actin and affect its polymerization have been 
widely used in experimental systems, and their activity can induce changes in cell fate in 
several contexts (65, 69).  However, they lack specificity to a particular type of actin, and 
their potential effect on cardiac and skeletal muscle actin fibers precludes their use in the 
clinic (101).  A way to safely modulate actin dynamics would be to target molecules 
associated with actin that are selectively upregulated in cancers.  For examples 
tropomyosin is a core component of actin filaments.  Different isoforms of tropomyosin 
exist and it is possible to affect actin filament compartments in cancer cells specifically, 
based on their tropomyosin isoform composition (111).  We took advantage of the fact 
that Ezrin, a known regulator of actin polymerization, is expressed in multiple types of 
cancers, but not in the normal tissue of origin of tumors (85-92).  Pharmacological 
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inhibition of Ezrin function allowed us to decrease the self-renewal potential of samples 
derived from human tumor xenogratfs.  Thus, targeting Ezrin through small molecule 
inhibitors has the potential to improve clinical outcome in multiple cancers and recently a 
screen of the Medicines for Malaria Venture Malaria Box uncovered a compound with 
potent anti-Ezrin activity and a favorable drug-likeness profile (112).  
 Importantly, we demonstrate that maintaining stemness through regulation of 
actin polymerization is a mechanism common to several pancreatic CSCs phenotypes. 
Upon loss of Ezrin expression we observed a decrease in the frequency of CD24+CD44+, 
CD44+cMet+, and ALDH+ phenotypes.  When we over activated the protein, the increase 
in CSC functions was accompanied by an increase in the frequency of CSC phenotypes. 
One potential barrier to the successful elimination of CSCs in pancreatic tumors is the 
existing phenotypic diversity.  Several pancreatic cancer CSC populations exist and the 
precise relationship between all of them is not completely characterized.  Studies to 
eliminate pancreatic CSCs have focused on targeting cell surface receptors of or signaling 
pathways active in some of theses populations and to date no study has demonstrated the 
elimination of more than two populations (13, 25, 56, 58, 59, 64, 113-115).  Our findings 
suggest that maintaining cell shape is a process fundamental to at least three CSC 
phenotypes, and thus targeting actin dynamics could lead to a successful elimination of 
all sources of self-renewal in the tumor. 
 Our observations could also be used to explain in part the role of desmoplasia in 
pancreatic cancer. The large deposition of extracellular matrix in pancreatic tumors 
would create a large compressive force and would also limit the space for cellular growth.  
These forces could cause changes in cellular shape and cytoskeletal organization, leading 
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to a loss of stemness.  A similar mechanism functions in the developing skeleton.  A rigid 
perichondrial membrane surrounds the primitive cartilage. Loss of this membrane results 
in unregulated growth in that tissue, most likely by allowing expansion of chondrocytic 
progenitors, rather then their differentiation into cartilage (116-118).  The collapse of 
stroma in mouse models of PDAC leads to an accelerated disease with a less 
differentiated phenotype, and an increase in the frequency of tumor initiating cells (119, 
120).  Thus, the ability to maintain a particular actin filament organization in the face of 
restrictive pressure from the stroma might be critical for stem cell maintenance and our 
observations corroborate this hypothesis. 
 Elucidation of the role of these processes will inform better therapeutic 
developments.  Our work demonstrates that actin cytoskeletal dynamics are a 
fundamental regulator of differentiation not only in normal systems, but also in CSCs. 
Manipulating actin polymerization and organization will improve clinical outcomes, by 
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